Trevi Therapeutics slides after launching $150 mln stock offering

Trevi Therapeutics

16/04/2026 21:32

** Trevi Therapeutics TRVI.O shares down 8% post-market to $13.38 as it seeks equity raise

** New Haven, Connecticut-based biopharma commences $150 mln stock offering

** Morgan Stanley, Leerink, Cantor and Stifel joint bookrunners

** Co plans to use net offering proceeds to fund clinical development of Haduvio for treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF ILD, and refractory chronic cough, among other uses, per the prospectus

** IPF is a chronic, progressive lung disease where tissue deep in the lungs becomes thick, stiff, and scarred

** With ~128.4 mln shares outstanding, TRVI has about $1.9 bln market cap

** TRVI stock finished up 1.9% at record high close of $14.54 on Thurs. Stock up 14% YTD including 30% rise over the past month

** Of 12 analysts covering the stock, 4 rate "strong buy", 8 rate "buy"; median PT $21, according to LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))